Abstract：
UNASSIGNED: This study aimed to evaluate whether cilostazol (phosphodiesterase III inhibitor) could enhance the healing of Achilles tendon ruptures in rats.
UNASSIGNED: The Achilles tendons of 24 healthy male adult rats were incised and repaired. The rats were randomly allocated to cilostazol and control groups. The cilostazol group received daily intragastric administration of 50 mg/kg cilostazol for 28 days, while the control group did not receive any medication. The rats were sacrificed on the 30th day, and the Achilles tendon was evaluated for biomechanical properties, histopathological characteristics, and immunohistochemical analysis.
UNASSIGNED: All rats completed the experiment. The Movin sum score of the control group was significantly higher (p = 0.008) than that of the cilostazol group, with means of 11 ± 0.63 and 7.50 ± 1.15, respectively. Similarly, the mean Bonar score was significantly higher (p = 0.026) in the control group compared to the cilostazol group (8.33 ± 1.50 vs. 5.5 ± 0.54, respectively). Moreover, the Type I/Type III Collagen ratio was notably higher (p = 0.016) in the cilostazol group (52.2 ± 8.4) than in the control group (34.6 ± 10.2). The load to failure was substantially higher in the cilostazol group than in the control group (p = 0.034), suggesting that the tendons in the cilostazol group were stronger and exhibited greater resistance to failure.
UNASSIGNED: The results of this study suggest that cilostazol treatment significantly improves the biomechanical and histopathological parameters of the healing Achilles tendon in rats. Cilostazol might be a valuable supplementary therapy in treating Achilles tendon ruptures in humans. Additional clinical studies are, however, required to verify these outcomes.
UNASSIGNED: The Achilles tendons of 24 healthy male adult rats were incised and repaired. The rats were randomly allocated to cilostazol and control groups. The cilostazol group received daily intragastric administration of 50 mg/kg cilostazol for 28 days, while the control group did not receive any medication. The rats were sacrificed on the 30th day, and the Achilles tendon was evaluated for biomechanical properties, histopathological characteristics, and immunohistochemical analysis.
UNASSIGNED: All rats completed the experiment. The Movin sum score of the control group was significantly higher (p = 0.008) than that of the cilostazol group, with means of 11 ± 0.63 and 7.50 ± 1.15, respectively. Similarly, the mean Bonar score was significantly higher (p = 0.026) in the control group compared to the cilostazol group (8.33 ± 1.50 vs. 5.5 ± 0.54, respectively). Moreover, the Type I/Type III Collagen ratio was notably higher (p = 0.016) in the cilostazol group (52.2 ± 8.4) than in the control group (34.6 ± 10.2). The load to failure was substantially higher in the cilostazol group than in the control group (p = 0.034), suggesting that the tendons in the cilostazol group were stronger and exhibited greater resistance to failure.
UNASSIGNED: The results of this study suggest that cilostazol treatment significantly improves the biomechanical and histopathological parameters of the healing Achilles tendon in rats. Cilostazol might be a valuable supplementary therapy in treating Achilles tendon ruptures in humans. Additional clinical studies are, however, required to verify these outcomes.
摘要：
■本研究旨在评估西洛他唑（磷酸二酯酶III抑制剂）是否可以增强大鼠跟腱断裂的愈合。
■切开并修复24只健康雄性成年大鼠的跟腱。将大鼠随机分为西洛他唑组和对照组。西洛他唑组每日灌胃50mg/kg西洛他唑28天,对照组未接受任何药物治疗。第30天处死大鼠,并对跟腱的生物力学特性进行了评估，组织病理学特征，和免疫组织化学分析。
■所有大鼠都完成了实验。对照组的Movinsum评分明显高于西洛他唑组(p=0.008),平均值分别为11±0.63和7.50±1.15。同样，与西洛他唑组相比，对照组的平均Bonar评分明显更高（p=0.026）（8.33±1.50vs.分别为5.5±0.54）。此外，西洛他唑组的I型/III型胶原比率（52.2±8.4）明显高于对照组（34.6±10.2）（p=0.016）。西洛他唑组的失效负荷明显高于对照组（p=0.034），这表明西洛他唑组的肌腱更强，对失败的抵抗力更强。
■这项研究的结果表明，西洛他唑治疗可显着改善大鼠跟腱愈合的生物力学和组织病理学参数。西洛他唑可能是治疗人类跟腱断裂的一种有价值的辅助疗法。额外的临床研究，然而,需要验证这些结果。
■切开并修复24只健康雄性成年大鼠的跟腱。将大鼠随机分为西洛他唑组和对照组。西洛他唑组每日灌胃50mg/kg西洛他唑28天,对照组未接受任何药物治疗。第30天处死大鼠,并对跟腱的生物力学特性进行了评估，组织病理学特征，和免疫组织化学分析。
■所有大鼠都完成了实验。对照组的Movinsum评分明显高于西洛他唑组(p=0.008),平均值分别为11±0.63和7.50±1.15。同样，与西洛他唑组相比，对照组的平均Bonar评分明显更高（p=0.026）（8.33±1.50vs.分别为5.5±0.54）。此外，西洛他唑组的I型/III型胶原比率（52.2±8.4）明显高于对照组（34.6±10.2）（p=0.016）。西洛他唑组的失效负荷明显高于对照组（p=0.034），这表明西洛他唑组的肌腱更强，对失败的抵抗力更强。
■这项研究的结果表明，西洛他唑治疗可显着改善大鼠跟腱愈合的生物力学和组织病理学参数。西洛他唑可能是治疗人类跟腱断裂的一种有价值的辅助疗法。额外的临床研究，然而,需要验证这些结果。
